Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

BPC-157

BPC-157, also known as Body Protection Compound-157, is a synthetic peptide derived from a naturally occurring protein found in human gastric juice. It is composed of 15 amino acids and is recognized for its potential healing and regenerative properties. BPC-1

BPC-157, also known as Body Protection Compound-157, is a synthetic peptide derived from a naturally occurring protein found in human gastric juice. It is composed of 15 amino acids and is recognized for its potential healing and regenerative properties. BPC-157 has shown promising results in preclinical research for treating various conditions, including muscle and tendon injuries, gastrointestinal disorders, and inflammation.

Its unique properties stem from its ability to accelerate wound healing, protect organs, and reduce inflammation. These characteristics make it of significant interest in both medical and research settings, particularly for treating injuries, promoting tissue repair, and potentially combating inflammatory diseases.

Category

Regenerative and Healing Peptide

Sequence

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Molecular Weight

Approximately 1419.55 g/mol

Molecular Formula

C62H98N16O22

Half Life

Less than 30 minutes

Most Common Uses

Tissue Repair and Healing

BPC-157 is widely studied for its ability to accelerate the repair of damaged tissues, including tendons, ligaments, and muscles. Preclinical studies suggest it enhances angiogenesis and collagen formation, promoting faster recovery from injuries. Athletes and people with musculoskeletal conditions often report using it to support rehabilitation.

Gastrointestinal Health

Due to its origin from gastric proteins, this peptide shows promise in addressing digestive system disorders. Research indicates it may protect and repair the gut lining, potentially benefiting conditions like inflammatory bowel disease, leaky gut syndrome, and gastric ulcers. It is also explored for mitigating damage from nonsteroidal anti-inflammatory drugs.

Neuroprotection and Cognitive Support

Emerging studies highlight BPC-157’s potential to support neurological health. Animal models demonstrate its capacity to promote nerve regeneration and protect against brain damage from trauma or toxins. Some users report improved mood and cognitive function, though human data remains limited.

Pain and Inflammation Management

BPC-157 is often used to alleviate chronic pain and reduce inflammation in various conditions. Its reported effects on modulating inflammatory pathways make it a candidate for managing arthritis, joint pain, and other inflammatory disorders. Users frequently describe reduced discomfort after administration.

Wound Healing

Beyond internal tissues, BPC-157 is investigated for its role in enhancing skin and wound repair. Studies suggest it speeds up the closure of cuts, burns, and surgical wounds by stimulating cellular migration and tissue regeneration. This makes it appealing in both medical and cosmetic contexts.

Mechanism of Action

BPC 157 works in different parts of the body to help with healing and reduce inflammation. It affects a natural process in the body that controls blood flow, helping more blood reach injured areas. This increased blood flow helps new blood vessels form and supports the rebuilding of tissues like muscles, tendons, and the lining of the stomach or intestines.

It also affects how certain genes work, helping cells survive and move to where they are needed for repair. It keeps the lining of blood vessels working properly and lowers the levels of substances that cause inflammation, making it easier for the body to heal. BPC 157 promotes the repair of skin and other tissues after injury by supporting signals that tell cells to grow and repair themselves.

Research shows it may help protect the stomach and intestines from damage caused by common painkillers, and it helps keep the inner lining of these organs healthy. Its effects are not just limited to one area and may also involve the brain and nerves, helping the body respond better to stress and injury.

Structure and Pharmacology

BPC-157 consists of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Derived from a human gastric protein, its molecular formula is C62H98N16O22, with a molecular weight of 1419.55 g/mol. This stable, water-soluble peptide resists degradation in the digestive tract, allowing for oral administration in addition to parenteral routes such as intramuscular or subcutaneous injection. Its compact structure enables efficient interaction with various biological systems, contributing to its broad therapeutic potential observed in preclinical studies.

Pharmacologically, BPC-157 exhibits rapid absorption following administration, with studies in rats and dogs indicating a half-life of less than 30 minutes after intravenous or intramuscular delivery. Despite this short half-life, its effects persist due to its ability to stimulate long-lasting cellular responses. The peptide distributes widely across tissues, particularly those involved in repair processes, such as muscles, tendons, and the gastrointestinal tract. It interacts with multiple pathways, including those regulating angiogenesis, collagen synthesis, and inflammation.

BPC-157 increases a natural substance in the body that helps form new blood vessels, supports the work of cells that rebuild tissue, and adjusts the body’s response to inflammation to help with healing. In the digestive system, it helps protect the stomach and gut lining and improves blood flow through natural chemical signals. Studies on the brain show it may affect mood-related chemicals like serotonin and dopamine, which could help protect the nervous system.

Metabolism of BPC-157 likely occurs through standard peptide degradation pathways, though specific metabolites remain understudied. Excretion is presumed to occur primarily through renal and hepatic routes, based on typical peptide pharmacokinetics. While animal studies provide robust data, human pharmacokinetic profiles are less defined, with ongoing research exploring its full pharmacological behavior.

Dosages

BPC-157 dosage information stems primarily from preclinical studies and anecdotal reports, as standardized human dosing guidelines remain absent due to limited clinical trials. In animal studies, typically involving rats and mice, doses range from 0.1 to 10 micrograms per kilogram of body weight, administered via intramuscular, subcutaneous, or oral routes. These studies often employ daily or twice-daily dosing regimens for periods spanning days to weeks, depending on the condition under investigation, such as tissue repair or gastrointestinal healing.

Human use, largely based on user experiences, commonly involves subcutaneous or intramuscular injections of 200 to 500 micrograms per day, often divided into one or two doses. Some users report oral administration at similar or slightly higher doses, citing the peptide’s stability in gastric environments. Dosing frequency and duration vary widely, with cycles typically lasting one to four weeks, followed by breaks to assess effects.

Due to the lack of regulatory approval and comprehensive human pharmacokinetic data, users often adjust doses based on personal response and tolerance. Ongoing research aims to establish evidence-based dosing protocols for therapeutic applications.

Warnings and Cautions

BPC-157 lacks regulatory approval for human use in most countries, and its safety profile in humans remains incompletely understood due to limited clinical trials. Users considering its use should exercise caution, as most data derive from preclinical studies and anecdotal reports. The peptide’s long-term effects are unknown, and repeated or high-dose use may pose unforeseen risks. Pregnant or breastfeeding women should avoid BPC-157, as no studies evaluate its safety in these populations. Administration, regardless of being subcutaneous, intramuscular, or oral, requires sterile techniques and proper handling to prevent infection or contamination.

Some users report mild side effects, such as transient discomfort at injection sites or gastrointestinal upset, though comprehensive adverse effect data are scarce. Sourcing BPC-157 from unregulated suppliers increases the risk of receiving impure or mislabeled products, which may lead to harm.

Research & Clinical Trials

Accelerator for Soft Tissue Healing

A thorough review of current research on BPC 157 found that this compound shows strong potential for helping heal and restore soft tissue injuries, such as those affecting tendons, ligaments, and muscles. Most of the studies so far have been done on small animals like rats, and they consistently show that BPC 157 speeds up healing in many types of injuries, caused by either trauma or internal problems. The results suggest that BPC 157 might be especially useful for treating tissues with poor blood flow and few cells, which usually take a long time to heal and don’t respond well to typical treatments. Besides helping with injuries at the site, BPC 157 also seems to improve muscle problems caused by broader health issues like high potassium or magnesium levels.

BPC-157 and Central Nervous System`

The study looked at how BPC-157 might help treat problems related to the brain and nerves. It focused on how this compound affects the connection between the gut and the brain, based on findings from three recent animal studies. The study found that BPC-157 helped protect the brain in rats that had stroke-like injuries caused by cutting off blood flow to the brain. It reduced both immediate and long-term brain cell damage and helped the rats regain memory, movement, and coordination. These improvements were linked to changes in brain tissue, where certain genes involved in blood vessel growth and brain protection became more active, which may explain how healing happened.

The study also showed that BPC-157 reduced stiffness and immobility caused by certain drugs, and improved symptoms similar to schizophrenia in rats, both in short-term and long-term experiments. These effects were linked to how BPC-157 balances systems in the body that involve nitric oxide and dopamine, helping to fix the problems caused by drugs like amphetamines and methamphetamine. In another test, rats with spinal cord injuries showed better healing and movement after being given BPC-157. The treatment helped nerves repair themselves, reduced swelling, improved blood flow, and stopped bleeding more effectively.

Possible Medical Application

BPC 157 shows strong promise as a potential treatment for a wide range of medical conditions, particularly those involving soft tissue injuries, inflammation, and even some central nervous system disorders. Preclinical studies in animals have consistently demonstrated that BPC 157 offers significant healing benefits across various organs and systems with few reported side effects. It has shown effectiveness in promoting tissue repair, reducing inflammation, and protecting against damage caused by harmful substances like NSAIDs and alcohol. It appears to interact with key biological systems, such as the nitric oxide pathway and antioxidant defenses, which may explain its broad therapeutic effects.

Sourcing

USA

LIMITLESS LIFE NOOTROPICS aka Biotech

Use Discount Code: EP20

SCANTIFIX

Use Discount Code: Exploringpeptides

Canada

BIOSLAB

Use Discount Code: EP10

Europe

DNLABResearch

Use Discount Code: EP15

Australia

LVLUPHEALTH

References

[1] Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and tissue research, 377(2), 153–159. https://doi.org/10.1007/s00441-019-03016-8

[2] Vukojevic, J., Milavić, M., Perović, D., Ilić, S., Čilić, A. Z., Đuran, N., Štrbe, S., Zoričić, Z., Filipčić, I., Brečić, P., Seiverth, S., & Sikirić, P. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural regeneration research, 17(3), 482–487. https://doi.org/10.4103/1673-5374.320969

[3] Józwiak, M., Bauer, M., Kamysz, W., & Kleczkowska, P. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals, 18(2), 185. https://doi.org/10.3390/ph18020185

Related articles

SLU-PP-915: Benefits, Research & Comparison with SLU-PP-332

Adalank vs Selank: Differences, Benefits and Effects

Adamax vs Semax: Comparison, Benefits, and Effects

Common Mistakes When Reconstituting Peptides

Peptides Vs Proteins: What’s The Difference?

What Are Peptides and How Do They Work?

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosage Protocols

Since BPC-157 is not FDA-approved for human use, there are no officially established dosing guidelines. The following information reflects dosages commonly reported in research literature and anecdotal use. Standard Dosing Range: Low dose: 200 to 250 mcg once daily Moderate dose: 250 to 500 mcg once or twice daily Higher dose: 500 to 800 mcg once or twice daily Weight-Based Dosing: Based on animal study extrapolations, an estimated human equivalent dose is approximately 1.6 mcg/kg body weight, translating to roughly 110 mcg for a 150-pound person and 145 mcg for a 200-pound person when using oral administration. Cycling Guidelines: Typical cycle length: 4 to 8 weeks Some users employ 4 weeks on, 2 to 4 weeks off protocols For acute injuries, shorter cycles of 2 to 4 weeks may be utilized Chronic conditions may warrant longer cycles under appropriate guidance
02

Question drills

Open a question for its connected answer.

01What If I'm 8 Weeks Post-ACL Reconstruction and Considering BPC-157?+

Consult your orthopedic surgeon before adding any compound to your rehab protocol. BPC-157 studied ACL injury recovery data suggests it works best during the inflammatory and early proliferative phases (weeks 0–4 post-injury), not during late-stage remodeling. By week 8, collagen deposition has already occurred. The peptide's primary mechanism may offer limited benefit at that stage. If your surgeon approves experimental use, subcutaneous administration near the surgical site is the route used in animal studies, not oral or systemic dosing.

SOURCE / realpeptides.co ↗
02What If BPC-157 Doesn't Produce Noticeable Improvement Within 4–6 Weeks?+

Cartilage turnover is slow. Type II collagen has a half-life measured in years, not weeks. The studies showing measurable regeneration used 4–8 week protocols, but symptomatic improvement (reduced pain, increased range of motion) often precedes detectable structural changes. If you're not experiencing any symptomatic benefit by week 6, reassess dosing (most studies used 10 µg/kg daily, which translates to roughly 700–800 µg/day for a 70–80 kg person), administration route (subcutaneous near the affected joint may be more effective than distal injection), and whether the product source meets research-grade purity standards. Underdosed or impure peptides won't replicate study outcomes.

SOURCE / realpeptides.co ↗
03What If a Researcher Needs Maximal Early Healing Speed?+

Use PRP or growth factor cocktails for the first 7–10 days. BPC-157 comparative studies show PRP delivers faster initial proliferation because it provides an acute bolus of PDGF, TGF-beta, and VEGF simultaneously. BPC-157's advantage emerges in the remodeling phase (days 14–28), where sustained angiogenesis and FAK signaling produce stronger, more organized tissue. For trauma models or time-sensitive endpoints, PRP may be the better choice. For studies measuring long-term tissue quality or functional recovery, BPC-157 consistently outperforms.

SOURCE / realpeptides.co ↗
04What If I Start at 250mcg and Experience Dizziness or Warmth at the Injection Site?+

Reduce the dose to 150mcg immediately and hold at that level for 7–10 days before attempting re-escalation. The dizziness is likely NO-mediated vasodilation. A transient effect that resolves as vascular tone adapts. Inject in the morning rather than evening to monitor symptoms during waking hours, and ensure adequate hydration (2–3 litres daily) to support lymphatic clearance.

SOURCE / realpeptides.co ↗
05What If Injection Site Reactions Occur with BPC-157?+

Reduce the injection volume and dilute the peptide further using sterile bacteriostatic water. BPC-157 is typically reconstituted at 5mg per 5mL, yielding 1mg/mL concentration. If injecting 0.5mL causes localized irritation, dilute to 0.5mg/mL and inject 1mL instead to deliver the same 500mcg dose. Injection site reactions (erythema, mild swelling) occur in approximately 15% of research participants and usually resolve within 48 hours. Persistent reactions beyond 72 hours warrant switching to a different injection site or reducing dose to 250mcg to assess tolerance.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Human & Animal Studies

Human Studies Human clinical evidence for BPC-157 is limited. Unlike FDA-approved medications, BPC-157 has not been evaluated in large, high-quality randomized controlled trials for common clinical uses such as tendon injury, ligament injury, muscle recovery, joint pain, wound healing, or gastrointestinal disease. Recent reviews describe BPC-157 as promising based on preclinical research but emphasize that available human evidence is insufficient to establish clinical safety or efficacy. A 2025 narrative review concluded that until well-designed human trials are conducted and published, BPC-157 should not be recommended for clinical use in musculoskeletal medicine. Animal & Preclinical Studies Most published BPC-157 research involves animal models and laboratory studies. Animal and preclinical studies have reported that BPC-157 may: Accelerate healing of transected rat Achilles tendon Improve medial collateral ligament healing in rats Stimulate tendon fibroblast outgrowth Promote cutaneous wound healing Support gastrointestinal mucosal protection Improve vascular and microcirculatory responses in injury models Reduce damage in certain inflammatory or drug-induced injury models These findings support biologic plausibility but do not prove that BPC-157 is safe or effective for the same conditions in humans.

POTENTIAL BENEFITS

Gastrointestinal Benefits of BPC 157

มันอาจลดความจำเป็นในการใช้ยาแก้ปวดแบบดั้งเดิมและเสนอทางเลือกที่ปลอดภัยกว่าสำหรับการจัดการความเจ็บปวดในระยะยาว คุณสมบัติในการฟื้นฟูของ BPC-157 เมื่อรวมกับความสามารถในการควบคุมการตอบสนองของภูมิคุ้มกันและรักษาสภาพการทำงานของเซลล์ ทำให้เป็น เปปไทด์ ที่มีประโยชน์หลากหลายพร้อมประโยชน์ต่อสุขภาพมากมาย BPC-157 ได้แสดงให้เห็นประสิทธิภาพที่โดดเด่นในการส่งเสริมการรักษาและปกป้องทางเดินอาหาร มันสามารถช่วยซ่อมแซมความเสียหายของเยื่อบุในกระเพาะอาหารและลำไส้ ซึ่งเสนอประโยชน์ที่อาจเกิดขึ้นสำหรับภาวะต่างๆ เช่น โรคลำไส้อักเสบ (IBD) เช่น ลำไส้ใหญ่อักเสบเป็นแผล และโรคกระเพาะBPC-157 แสดงผลลัพธ์ที่น่าสนใจในการรักษาแผลในกระเพาะอาหาร [4] เพนทาเดคาเปปไทด์ นี้ยังได้รับการพิสูจน์ทางการแพทย์ในหนูว่าสามารถรักษา GI Fistulas ซึ่งเป็นความผิดปกติในระบบย่อยอาหาร
05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 Gastric Protection Results Timeline Expect: Comparison

BPC-157 VEGF/FGF upregulation, angiogenesis, NOS modulation 3–7 days (mucosa stabilisation) 14–28 days (epithelial closure) Unknown. Limited long-term human data Most direct pro-r…